Based on the Pro Medicus Limited stock forecast from 0 analysts, the average analyst target price for Pro Medicus Limited is not available over the next 12 months. Pro Medicus Limited’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Pro Medicus Limited is Slightly Bullish , which is based on 7 positive signals and 5 negative signals. At the last closing, Pro Medicus Limited’s stock price was USD 112.00. Pro Medicus Limited’s stock price has changed by +11.44% over the past week, +16.13% over the past month and +148.06% over the last year.
No recent analyst target price found for Pro Medicus Limited
No recent average analyst rating found for Pro Medicus Limited
Company Overview Pro Medicus Limited
Pro Medicus Limited, a healthcare informatics company, engages in the development and supply of healthcare imaging software, and radiology information (RIS) system software and services to hospitals, imaging centers, and health care groups in Australia, North America, and Europe. The company offers Visage RIS Visage 7 Enterprise Imaging Platform, a healthcare imaging software that provides radiologists, physicians, and clinicians with access and visualization capability for viewing 2-D, 3-D, and 4-D medical images; and picture archive and communication system (PACS)/digital imaging software. It also provides Visage RIS, a proprietary medical software for practice management, training, installation, professional services, and after-sale support and service products; Promedicus.net, an e-health platform for secure email and integration products. In addition, the company offers Visage Ease Pro, a mobile application that provides users the ability to interpret various diagnostic imaging studies stored on a Visage 7 server. The company was incorporated in 1983 and is headquartered in Richmond, Australia. Read Less
Pro Medicus Limited, a healthcare informatics company, engages in the development and supply of healthcare imaging software, and radiology information (RIS) system software and services to hospitals, imaging centers, and health care groups in Australia, North America, and Europe....Read More
Frequently Asked Questions About Pro Medicus Limited (PMCUF) Stock
Stock Target Advisor's fundamental analysis for Pro Medicus Limited's stock is Slightly Bullish .
PMCUF stock's dividend yield is 0.26%.
Our analysis grades PMCUF stock's dividend yield at F. This means that PMCUF stock's dividend yield is above 11% of the stocks in the Health Information Services sector in the OTC exchange.
Based on this PMCUF may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on PMCUF's stock to indicate what its average analyst target is.
PMCUF stock's Price/Earning ratio is 211.32.
Our analysis grades PMCUF stock's Price / Earning ratio at F. This means that PMCUF stock's Price/Earning ratio is above 91% of the stocks in the Health Information Services sector in the OTC exchange.
Based on this PMCUF may be a overvalued for its sector.
The last closing price of PMCUF's stock was USD 112.00.
The most recent market capitalization for PMCUF is USD 11.78B.
Unfortunately we do not have enough analyst data on PMCUF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Pro Medicus Limited's stock.
As per our most recent records Pro Medicus Limited has 0 Employees.
Pro Medicus Limited's registered address is 450 Swan Street, Richmond, VIC, Australia, 3121.
You can get more information about it from Pro Medicus Limited's website at https://www.promed.com.au.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Pro Medicus Limited (PMCUF) Stock
Stock Target Advisor's fundamental analysis for Pro Medicus Limited's stock is Slightly Bullish .
PMCUF stock's dividend yield is 0.26%.
Our analysis grades PMCUF stock's dividend yield at F. This means that PMCUF stock's dividend yield is above 11% of the stocks in the Health Information Services sector in the OTC exchange.
Based on this PMCUF may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on PMCUF's stock to indicate what its average analyst target is.
PMCUF stock's Price/Earning ratio is 211.32.
Our analysis grades PMCUF stock's Price / Earning ratio at F. This means that PMCUF stock's Price/Earning ratio is above 91% of the stocks in the Health Information Services sector in the OTC exchange.
Based on this PMCUF may be a overvalued for its sector.
The last closing price of PMCUF's stock was USD 112.00.
The most recent market capitalization for PMCUF is USD 11.78B.
Unfortunately we do not have enough analyst data on PMCUF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Pro Medicus Limited's stock.
As per our most recent records Pro Medicus Limited has 0 Employees.
Pro Medicus Limited's registered address is 450 Swan Street, Richmond, VIC, Australia, 3121.
You can get more information about it from Pro Medicus Limited's website at https://www.promed.com.au.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PMCUF !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
